THE LONG AND SHORT OF GLP-1 AGONISTS: A Practical Approach to the Complex Nature of T2DM Management
A CME-certified Symposium



Registration Statement


By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements below.


Registration

  VenueCityStateDate
View Agenda  Walter E. Washington Convention Center
Room: Salon GHI
WashingtonDC Tuesday
May 3, 2016 12:00 PM


This event is not a part of the official Internal Medicine Meeting 2016 Education Program.


Downloadables


Download (PDF) Program Slides Download (PDF)

Download (PDF) Program Slides Download (PDF) (Coming Soon)

Program Description

The landscape of type 2 diabetes mellitus (T2DM) management is continuously changing and evolving. Newly released guideline recommendations on the management of T2DM, along with approvals of new agents for the treatment of this disease, create a need among internists and primary care physicians (PCPs) to understand how to appropriately individualize therapy, step-up therapy sooner to achieve HbA1c goals, and recognize the efficacy/safety issues associated with these new antihyperglycemic agents. Low acceptance of injectables remains a significant issue in the optimal management of patients with T2DM. Involving patients in individualized treatment decisions can address and break down treatment barriers, including injection anxiety. 

The Long and Short of GLP-1 Agonists: A Practical Approach to the Complex Nature of T2DM Management will explore these issues and discuss the most up-to-date information in T2DM management and best practices in patient engagement.

Case Consult

To submit your challenging case to the faculty and receive expert opinions and recommendations on management choices at this program, please email your case to mfeeley@rockpointe.com by Friday, April 22, 2016. All case information will be kept confidential and presented anonymously.

Target Audience

This activity is intended for internists and primary care physicians (PCPs) who manage patients with T2DM.

Educational Objectives

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Describe the HbA1c-lowering properties of GLP-1 receptor agonists and their impacts on weight and blood pressure, as well as their safety profiles including hypoglycemic risk
  • Discuss the use of GLP-1 receptor agonists to provide glycemic control in combination with oral agents and/or insulin with a goal of reducing long-term microvascular and macrovascular risks
  • Develop a collaborative approach to T2DM management that empowers patients by providing individualized patient education to address and break down treatment barriers, including injection-related barriers

Program Faculty

Lawrence Blonde, MD, FACP, FACE
Ochsner Diabetes Clinical Research Unit
Frank Riddick Diabetes Institute
Department of Endocrinology
Ochsner Medical Center
New Orleans, LA

Richard E. Pratley, MD
Medical Director, Florida Hospital Diabetes Institute
Senior Investigator, Translational Research Institute for Metabolism and Diabetes
Adjunct Professor, Sanford Burnham Prebys Medical Discovery Institute at Lake Nona
Orlando, FL


Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Designation Statement


The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit or the evaluation, please email contact@potomacme.org.


Disclosure Information


Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias. 

FDA Disclosure

The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses. 


Method of Participation


To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME certificate will be emailed within 2 weeks upon submission of a completed evaluation form.

There is no fee associated with this program.


Special Services


Event staff will be glad to assist you with any special needs. Please email specialservices@rockpointe-pcme.com at least 5 days prior to the program.  

PROVIDED By


Jointly provided by Potomac Center for Medical Education and Rockpointe


      

SUPPORTED BY


This activity is supported by an educational grant from Lilly.



Registration

  VenueCityStateDate
View Agenda  Walter E. Washington Convention Center
Room: Salon GHI
WashingtonDC Tuesday
May 3, 2016 12:00 PM